Valeant Inks $344M Deal For Skin Care Co. Obagi
Canadian drugmaker Valeant Pharmaceuticals International Inc. will pay $343.8 million for skin care specialist Obagi Medical Products Inc. in a move that reinvigorates its dealmaking activity after a flurry of big-ticket...To view the full article, register now.
Already a subscriber? Click here to view full article